279 results about "PLT - Platelets" patented technology

The invention relates to the technical field of biological medicine, in particular to a reagent combination, a kit and a detection method for detecting a platelet activation marker PAC-1. The reagent combination comprises a first detection probe, a second detection probe, a third detection probe and a fourth detection probe, the first detection probe is at least formed by coupling DNA1 and a PAC-1 antibody 1; the second detection probe is at least formed by coupling a PAC-1 antibody 2 and DNA2; the third detection probe is DNA3 for marking fluorescent molecules; and the fourth detection probe is an antioxidant combined on a carrier molecule. When the reagent combination or the kit is used for detecting the PAC-1, the cost is low, whole blood can be used for detection, convenience and rapidness are achieved, meanwhile, artificial platelet activation in an in-vitro sample is avoided, in addition, the detection operation process is simple, the overall detection time is short, and the practical requirement for clinical detection of the PAC-1 is met.

The present disclosure provides processes for preparing cryopreserved platelets, compositions comprising frozen platelets in a cryopreservation medium, and a collection of cryo-vessels comprising cryopreserved platelets. In some aspects, provided herein are processes for preparing cryopreserved platelets from a platelet pool of more than 1 donor to provide collections of cryopreserved platelets with improved vial to vial and lot to lot consistency for example, in DMSO concentration. Also provided herein is a collection of cryo-vessels, each comprising cryopreserved platelets having a biomolecule profile indicative of more than 1 platelet donor. Furthermore, provided herein are compositions comprising frozen platelets that when stored at a temperature in a range of -10°C to -30°C, for at least 1 month are capable of yielding a platelet count of at least 1.0 x 1011 / 35 ml of the composition and other recited properties

The invention relates to the technical field of blood separation, in particular to a platelet concentration-based gravity separation system, which comprises a tension disturbance extraction module, a viscosity response positioning module, a sedimentation retarding judgment module, a platelet export judgment module and a concentration layer interface output module. According to the method, real-time extraction of tension change frequency and mutation amplitude is introduced, and a normalization processing mode of disturbance polymerization indexes is combined, so that a mechanical unstable area under tiny disturbance in the blood standing sedimentation process is effectively described, and the sensitive recognition capability on potential layered behavior changes is enhanced. Through continuous tracking of a viscosity behavior curve in a disturbance time period, an accurate time anchor point is provided for judgment of a subsequent liquid column motion state. On the basis of microscopic changes of the liquid column height and the rate, through combined judgment of the acceleration change trend and the attenuation amplitude, the settlement state is distinguished no longer depending on a macroscopic parameter threshold value, but is dynamically regulated and controlled through the change trend and a fluctuation sequence.

The invention discloses a diabetic nephropathy risk assessment and prediction system based on platelet indexes, and particularly relates to the technical field of disease risk prediction, which comprises a platelet index acquisition module, a drug use data acquisition module, a drug intervention assessment module, an index correction module, a clustering analysis module and a diabetic nephropathy risk assessment module, the method comprises the following steps: acquiring platelet related detection indexes and historical medication data of a patient, calculating a drug intervention influence index and generating a correction factor, realizing platelet index reverse reduction correction by adopting a convolutional neural network model, determining a similar group in combination with clustering analysis, and dynamically evaluating the risk of diabetic nephropathy based on the average morbidity of the group. Personalized accurate prediction is realized; the platelet index correction accuracy is improved, individualized drug intervention elimination is achieved, the similar population clustering analysis precision is enhanced, diabetic nephropathy risk prediction is dynamically adjusted in combination with comprehensive scores, and the early screening and individualized intervention effects are improved.

The invention discloses a platelet performance index evaluation method and device. The method comprises the following steps: collecting platelets to be detected through a platelet performance index evaluation method; acquiring cloud feature data of the to-be-detected platelets by using an image video device, wherein the cloud feature data comprises cloud feature image data and / or cloud feature video data; and evaluating platelet performance indexes by using the cloud feature data of the to-be-detected platelets. The platelet performance indexes can be accurately and rapidly detected at low cost, and the problems that a traditional platelet performance detection method is long in consumed time, high in cost, large in result error and the like are solved.

The invention relates to the technical field of medical artificial intelligence, in particular to a vascular embolism risk prediction method based on big data analysis, and the method comprises the steps: collecting a pulse pressure fluctuation rate, a microcirculation resistance index and a platelet adhesion gradient through a multi-source sensor, and extracting dynamic physiological parameter time sequence features; constructing a hemodynamic finite element model based on CTA and VFI image data, and obtaining a vascular mechanical feature vector; deep coupling of the pulse pressure spectrum and the circumferential stress is achieved through dynamic time warping and convolution mapping, and a multi-modal risk feature set is generated; and performing cross-modal coding by using the double-branch graph neural network, and outputting an acute embolism probability and a three-dimensional risk thermodynamic diagram. According to the method, physiological, image and mechanical multi-dimensional information is fused, and the method has the advantages of being high in real-time performance, accurate in positioning and good in interpretability and is suitable for risk prediction and auxiliary diagnosis of clinical cardiovascular and cerebrovascular events.

The invention discloses an MYH9-RD auxiliary screening system and an MYH9-RD auxiliary screening method based on blood cell morphology. Comprising an image acquisition module, an image detection module and an image analysis module, wherein the image acquisition module is responsible for acquiring a Wright stained peripheral blood image of a case to be screened; the image detection module is responsible for acquiring an independent image of each blood cell; the image analysis module is responsible for acquiring blood cell category information, leukocyte form information and platelet size information; the counting and processing module is responsible for generating an analysis result of a case to be screened; the related disease judgment module is responsible for generating an MYH9-RD screening result; and the result output module is responsible for outputting the screening result. According to the method, the morphology of the special cells of the peripheral blood is accurately identified and the number of the cells is accurately calculated through an artificial intelligence algorithm, so that the defects of incomplete visual capture and easy fatigue of human beings are overcome, misdiagnosis and missed diagnosis caused by personal errors or subjective differences are reduced, accurate identification of the cell morphology is realized, and the working efficiency is greatly improved; and early, rapid and efficient screening of the MYH9-RD is facilitated.

The invention discloses a concentration composite detection method for platelet-rich plasma. The method comprises the following steps: acquiring a platelet concentration measurement value sequence of the platelet-rich plasma; performing transmittance measurement on the platelet-rich plasma to obtain a transmittance measurement value sequence; preprocessing the platelet concentration measurement value sequence and the transmittance measurement value sequence to obtain a preprocessed sequence set; and performing composite detection processing on the pre-processing sequence set to obtain blood concentration detection result information. The platelet concentration can be rapidly and accurately detected in the platelet-rich plasma collection process.

The invention relates to the technical field of platelet-rich plasma preparation, and discloses a platelet-rich plasma preparation device and a preparation method thereof.The platelet-rich plasma preparation device comprises a split type cabin, a red blood cell cabin cover and a PRP cabin cover, and the red blood cell cabin cover and the PRP cabin cover are connected to the two ends of the split type cabin in a threaded mode; compared with a traditional mode that the locking rods are fixedly connected into the cabin, according to the preparation device, the locking rods are movably connected into the cabin, when the cabin needs to be locked, the corresponding driving blocks are pressed, the driving blocks push the locking rods, and the locking rods can be locked through the driving blocks. The locking rod is inserted into the hole of the communicated cabin for blocking and locking, the traditional mode that the length of the cabin is shortened by screwing the cabin and the locking rod is inserted into the hole of the communicated cabin for blocking and locking is changed, screwing is not needed, and the accident that plasma leaks out due to the fact that connection of the cabins falls off due to the fact that the screwing direction is wrong is avoided.

The invention discloses a micro-fluidic chip for separating platelet-rich plasma and a use method of the micro-fluidic chip. The micro-fluidic chip comprises a sample injection chamber, a red blood cell storage chamber, a red blood cell collection chamber, a PRP collection chamber, a PPP collection chamber, a boundary layer detection channel, a red blood cell extraction channel, a PRP extraction channel and a PPP extraction channel, the red blood cell collection chamber, the PRP collection chamber and the PPP collection chamber are provided with corresponding negative pressure output channels and negative pressure interfaces. By adopting the micro-fluidic chip disclosed by the invention, platelet-rich plasma can be separated in a closed chip in the whole process, and external pollution is avoided. The operations of centrifugal layering, red blood cell extraction, plasma extraction, PRP enrichment and the like in the PRP preparation process are all continuously carried out, so that the PRP preparation time can be effectively shortened.

The invention discloses a pulmonary arterial hypertension diagnosis and severity degree judgment prediction model based on myocardial magnetic resonance, a construction method and application. Through statistical analysis of myocardial magnetic resonance and test information of a pulmonary hypertension patient and a contrast, specific indexes of the pulmonary hypertension patient are screened out, and new clinical models for pulmonary hypertension diagnosis are respectively constructed. The model comprises five independent predictive variables: ascending aorta width, left atrial anterior-posterior diameter, left ventricular ejection fraction, pulmonary artery width and platelet level; the invention further discloses a pulmonary arterial hypertension severity prediction model. The model comprises two independent prediction variables, namely the left ventricular end diastolic volume index and the body weight. The constructed diagnosis prediction model is based on Lasso regression and Logistic regression technologies, the dependence on traditional invasive right heart catheter examination is effectively reduced, the comfort level of a patient is greatly improved, the diagnosis process is optimized, and the overall diagnosis efficiency is improved.

The invention discloses a clinical prediction model for the probability of occurrence of spleen hyperfunction of a hepatolenticular degeneration patient and a design method, and belongs to the technical field of medical information. The clinical prediction model comprises an input module for receiving patient parameter indexes consisting of an aspartate aminotransferase and platelet ratio index (APRI), a hepatic fibrosis 4 index (FIB-4), a liver hardness value (LSM) and a portal vein diameter (PVD); the processing module is connected with the input module and calculates the prediction probability of the patient according to the model; and the output module is connected with the processing module and outputs the risk probability of occurrence of the hypersplenic function of the hepatolenticular degeneration patient obtained by the clinical prediction model. The clinical prediction model established by the invention has good distinction degree, calibration degree and clinical practicability, has relatively high accuracy, and can be conveniently used for early recognition and risk prediction of hypersplenic function of hepatolenticular degeneration patients.

The invention relates to a postoperative hypoxemia risk prediction method and system.The postoperative hypoxemia risk prediction method comprises the steps that patient data are obtained, and the patient data comprise the body mass index, the platelet count, the fibrinogen level and the triglyceride-glucose index; the patient data are input into a pre-trained postoperative hypoxemia risk prediction model to obtain a postoperative hypoxemia risk prediction result, and the postoperative hypoxemia risk prediction result comprises the postoperative hypoxemia occurrence probability, the 95% confidence interval and the model parameters. The method has the advantages that the preoperative data, namely BMI, PLT, FIB and TyG, can be used for predicting the postoperative hypoxemia risk of the patient, so that the patient with high postoperative hypoxemia risk can be focused after the operation; preoperative data is easy to obtain and can be obtained from routine examination of a patient, and the method is simple, rapid and convenient to operate; the speed of obtaining the postoperative hypoxemia risk prediction result is high, and the accuracy rate is high.

The present invention relates to methods for determining a blood gas parameter and / or a basic metabolic panel parameter in a blood sample comprising combining the blood sample with an anti-coagulant and an anti-platelet agent, and determining said blood gas parameter and / or parameter in the sample. In some aspects, the invention relates to determining said parameters in samples that have been subjected to pre-analytical stress.

To provide a specimen measurement device and a specimen measurement method that readily confirms the suitability of a sample as platelet-rich plasma.SOLUTION: A specimen measurement device 1 comprises a test section 13 for measuring optical information of platelet-rich plasma and platelet-poor plasma prepared from a blood specimen, a control sections 210 and 213 for acquiring information regarding platelet aggregation of the blood specimen based on the optical information of the platelet-rich plasma and platelet-poor plasma, and a display 4 for displaying information regarding platelet aggregation. The control sections 210 and 213 acquire evaluation information regarding the suitability of the platelet-rich plasma as a sample based on the measurement results of the platelet-rich plasma by the test section 13, and make the display 4 display the information.SELECTED DRAWING: Figure 15

In the agglutinated platelet parameter detection method and the identification AI training method thereof, a blood sample is preprocessed, and a microscopic examination sample is obtained and tiled; standing the platelets to sink to the bottom; shooting to obtain a microscopic examination sample image; according to the method, normal platelets and agglutinated platelets are identified and labeled, a labeled picture is obtained for AI training, an obtained AI feature data set A comprises normal platelet features, and an AI feature data set A comprises agglutinated platelet features. Identifying a microscopic examination sample image by using an AI identification algorithm, identifying agglutinated platelets in the blood sample in a selected area S1 of the image, and obtaining the total number NUMS1 of the agglutinated platelets in the blood sample in the selected image; and the AI recognition algorithm recognizes the agglutinated platelets in the blood sample according to the agglutinated platelet feature data set. The recognition of the agglutinated platelets is completed by utilizing advanced AI computing power, so that the analysis of the agglutinated platelets is more efficient and more accurate, and the dimension of platelet function analysis based on images is expanded.

The invention relates to an automatic plasma collection device which comprises a sample suction needle, a mechanical arm, a suction device and a control device, and an outer tube conductive end is formed at the sample suction end of an outer tube of the sample suction needle; the inner tube of the sample suction needle exposes the conductive material at the sample suction end to form an inner tube conductive end; the sample suction needle is also provided with a non-conductive plug which is connected with the outer tube and the inner tube at the sample suction end; the control device controls the mechanical arm, the suction device and the sample suction needle to automatically collect plasma based on electric signals formed by the outer tube conductive end and the inner tube conductive end. The invention further relates to an automatic platelet aggregation detection method based on the single PRP plasma, and the light transmittance A of the light waves of the multiple wavelengths of the PPP plasma is calculated based on the light transmittance A of the light waves of the multiple wavelengths of the PRP plasma by means of the trained prediction model, so that the maximum platelet aggregation rate is calculated. The device and the method realize the automation of platelet aggregation function detection, simplify the detection process, remarkably improve the detection efficiency and reduce the detection cost.

The invention relates to a liver cirrhosis prediction and noninvasive diagnosis system and method for autoimmune hepatitis, and belongs to the technical field of medicine. The system comprises a data acquisition module, a data processing module and a model construction module. The data acquisition module is used for acquiring blood detection indexes of a patient, including total protein, albumin, total bilirubin, direct bilirubin, aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), glutamyltranspeptidase (GGT), urea, creatinine, platelet count (PLT) and the like. The model building module is combined with blood detection data and clinical pathology data, a statistical analysis method such as binary Logistic regression is adopted, and a liver cirrhosis prediction model is trained and built. Based on four key blood detection indexes, the method can effectively predict the occurrence of liver cirrhosis of AIH patients, and especially provides a scientific reference for noninvasive diagnosis and curative effect monitoring for patients who cannot perform liver puncture or reject liver puncture.

The invention discloses a blood routine examination and immunochromatography combined detection reagent card, and belongs to the technical field of medical detection, the blood routine examination and immunochromatography combined detection reagent card comprises a reagent card body, the reagent card body comprises a detection counting area, a reagent liquid filling area and a sampling area, the sampling area is used for accommodating a sample and pre-diluting the sample, the reagent liquid filling area is used for treating and diluting the sample, and the detection counting area is used for counting the detection counting area. The detection counting area comprises a red blood cell counting square groove, a white blood cell counting square groove and a blood platelet counting square groove. Five groups of neutrophil, lymphocyte, mononuclear cell, eosinophilic granulocyte and basophilic granulocyte in leukocyte are realized, and promotion of a basic POCT instrument can be promoted by matching with other necessary blood routine parameters and CRP, SAA, glycosylated hemoglobin and other parameters. The operation of a user is convenient, the joint detection test of blood routine examination and immunochromatography items can be fully automatically completed by one reagent card and the immunochromatography card, and extra dilution of a sample is not needed.

The invention discloses a low-molecular-weight heparin precise drug delivery decision system and method based on expert rules, and relates to the technical field of medical data intelligent processing, the system comprises a data acquisition module and an expert rule module, the expert rule module comprises a first rule subset, a second rule subset, a third rule subset and a fourth rule subset; the analysis module is used for analyzing the thrombin time data and the platelet counting data according to a second rule subset and a third rule subset in the expert rule module to obtain a bleeding risk assessment result; and the administration dosage determination module is used for calling corresponding dosage parameters from the expert rule module according to the weight grading result of the expert rule module and the bleeding risk assessment result of the analysis module, adjusting the dosage parameters and determining the administration dosage of the low-molecular heparin. According to the method, key physiological data such as the body weight, the thrombin time and the platelet counting of a patient are collected, and an expert rule base is introduced, so that accurate personalized adjustment of the dosage of the low-molecular-weight heparin is realized.

Provided is a method for assisting in grasping the status of platelet activation, by developing a biomarker that more accurately reflects platelet activation in vivo, said method being usable in testing for thrombotic hemostatic diseases. The method for assisting in grasping the status of platelet activation comprises (1) measuring the concentration of soluble CLEC-2 and a platelet count in a sample obtained from a subject, and (2) calculating a value of [soluble CLEC-2 concentration] / [platelet count] by dividing the soluble CLEC-2 concentration by the platelet count. If desired, the method may further comprise (3) comparing the value with a value of [soluble CLEC-2 concentration] / [platelet count] obtained by using samples from healthy persons.

Disclosed herein are methods, biomarkers, systems, compositions and kits for determining the phase or metabolic state (e.g. First Phase, Second Phase, or Third Phase) of a red blood cell (RBC) sample or for determining the phase or metabolic state (e.g., First Phase or Second Phase) of a platelet (PLT) cell sample. The methods disclosed herein are related to the use of isolated RBC sample or isolated PLT sample and analytical tools for providing information that is relevant to the phase or metabolic state of the RBC sample or the PLT sample. The system disclosed herein utilizes isolated RBC sample or isolated PLT sample and at least one analytical tool or an output from the at least one analytical tool. The compositions and kits described herein utilize RBC samples or PLT samples, including compositions in a form that allows for analysis of the RBC sample or the PLT sample.

The invention discloses a hematology analyzer and a platelet numerical value measuring method, in the hematology analyzer, an analysis unit is used for receiving a pulse signal to generate a first image, receiving an optical signal to generate a second image, obtaining a platelet original numerical value based on the first image, obtaining an interference coefficient of a leukocyte fragment based on the second image, and obtaining the platelet numerical value based on the interference coefficient; and obtaining a platelet measurement value based on the platelet original value and the interference coefficient. Through the cooperation of the impedance module and the flow fluorescence module, the platelet original value in the blood cell sample and the interference coefficient of the leukocyte fragment are detected, and the accuracy of each step in the calculation process of the platelet measurement value is ensured. Meanwhile, the platelet measurement numerical value is calculated through the analysis unit based on the platelet original numerical value and the interference coefficient, so that the accuracy of the blood cell analyzer for measuring the platelet measurement numerical value is improved, the practicability of the blood cell analyzer is improved, and the use experience of a user on the blood cell analyzer is improved.

A sample measuring apparatus according to an embodiment may be a sample measuring apparatus for measuring a platelet aggregation function of a blood sample. The apparatus may include: a detection section configured to measure optical information of platelet rich plasma and platelet poor plasma prepared from a blood sample; a control section configured to acquire information on a platelet aggregation function of the blood sample based on optical information of platelet rich plasma and platelet poor plasma; and a display configured to display information on a platelet aggregation function. The controller is configured to obtain evaluation information on suitability of the platelet-rich plasma as a sample based on a measurement result of the platelet-rich plasma by the detection portion, and display the evaluation information on the display.

The invention belongs to the field of medical examination, and particularly relates to a whole blood quantitative platelet aggregation capability detector and a detection platform. The detection platform comprises a detector and a reagent card; the detector comprises a reagent card accommodating bin, a control module, an automatic sample injection module, a motor stirring module, a temperature control module, a light path detection module and a data display and printing module, the automatic sampling module is used for automatically extracting and adding a blood sample in the reagent card according to the obtained code scanning information; the motor stirring module outputs an instruction for controlling a detection motor through the control module according to the stirring frequency preset by software, and stirs the reaction in the detection bin through the rotation of the detection motor; the temperature control module is used for simulating an in-vivo reaction environment in the temporary storage bin and the detection bin of the reagent card; the light path detection module is used for detecting luminosity value change caused by polymerization reaction of the blood sample and calculating to obtain an experimental result; and the data display and printing module is used for displaying and printing a final experiment result.

The utility model provides a blood sampling and centrifuging integrated platelet-rich plasma preparation device which comprises a centrifugal sleeve and a blood sampling assembly coaxially and detachably installed in the centrifugal sleeve, and the blood sampling assembly comprises a blood collecting tube and a vein puncture needle connected to the head end of the blood collecting tube; the outer wall of the blood collecting tube is provided with a needle head containing bin used for containing a needle head of the vein puncture needle. According to the blood collection and centrifugation integrated platelet-rich plasma preparation device, a container does not need to be replaced in the blood collection and centrifugation process, and contact between the blood and the outside is reduced; and the needle head of the vein puncture needle can be properly stored, so that bacterial contamination is really avoided. Moreover, the needle head is accommodated in the needle head accommodating bin, so that the requirement on the length of the centrifugal sleeve can be reduced, and the blood carrying amount of the centrifugal sleeve with the same size is more.

The present invention relates to the technical field of platelet function analysis equipment, and specifically relates to a platelet function analysis equipment, mainly including a machine body. A support plate is fixedly installed on the top surface of the machine body, and a fixing plate is fixedly installed on the top surface of the support plate. A cover body is rotatably connected to the top surface of the fixing plate. A reagent tube is arranged below the cover body. An adjusting mechanism is arranged above the support plate. A fixing mechanism is arranged inside the fixing plate. A pressing mechanism is arranged above the fixing box. By pushing the moving plate with a buckle, the moving plate squeezes the airbag. The airbag contracts under the extrusion, and the gas inside is transported to the fixing box through the connecting pipe, pushing the piston plate to move. When the piston plate moves, it drives the support rod and the clamping plate to move, and the clamping plate clamps and fixes the reagent tube. When vibration or external force acts during the detection process, the reagent tube is not likely to shake or loosen, improving the stability of the reagent tube and the accuracy of the detection result, and thus ensuring the reliability of the overall analysis.

The invention relates to the technical field of biology, and discloses a method for detecting thrombin production promotion capability of extracellular vesicles in a blood sample, which comprises the following steps: centrifuging the blood sample collected within 2 hours at 2500g at room temperature for 15 minutes, sucking upper platelet-deficient plasma and placing in a centrifuge tube, centrifuging at 2500g at room temperature again for 15 minutes, and sucking upper platelet-free plasma; centrifuging the obtained platelet-free plasma at 4 DEG C at 20000g for 1 hour; and sucking the upper-layer extracellular vesicle-free plasma for later use, taking the obtained extracellular vesicle precipitate as a to-be-detected sample, and detecting the thrombin generation promotion capability of the extracellular vesicles by using a thrombin generation analyzer. The method provided by the invention can be used for accurately detecting the capability of the extracellular vesicles in the blood sample for promoting thrombin generation, has the advantages of convenience in operation, easiness in obtaining the sample, noninvasiveness, no damage, high detection speed, low cost and the like, has important significance on thrombus risk assessment and prediction, and has better clinical application value.

The invention provides a micro-fluidic chip for detecting platelet aggregation function, and relates to the technical field of platelet aggregation function detection.The micro-fluidic chip comprises a chip body, the chip body is provided with at least one group of detection parts, and each group of detection parts comprises a sample adding groove and at least one group of detection units; the detection unit comprises a coating runner and a reaction cavity; the inner wall of the coating flow channel is coated with an activating agent coating, and the length extending direction of the coating flow channel is inclined relative to the radial direction with the rotation center as the circle center, so that the proximal end and the distal end of the coating flow channel are located on different radial lines with the rotation center as the circle center respectively. Through the arrangement, local retention or dead zones are avoided, the detection efficiency is improved, the dissolution rate of the activator is effectively improved, the dissolution rate of an activator coating is more than 5 mu g / s, the activator is ensured to be fully dissolved, the error absolute value of the final concentration of the activator in a sample is less than 6%, the detection error is reduced, and the detection accuracy is improved.

A system includes: a dialysis machine configured to provide a dialysis treatment for a patient; at least one fluid line; a sensor disposed on the at least one fluid line, wherein the sensor is configured to obtain platelet measurements from fluid passing through the at least one fluid line; and a processing system configured to: receive the platelet measurements from the sensor; determine whether the platelet measurements are indicative of a risk of Heparin-induced thrombocytopenia (HIT) to the patient; and in response to determining that the platelet measurements are indicative of a risk of HIT to the patient, provide an alert to the patient and / or a clinician based on the platelet measurements.